Mazdutide’s Weight‑Loss Promise – Too Good to Be True or Next Big Step?
Posted by sleep_coastal in Research & News - 1 points, 0 comments.
A JAMA Phase‑3 trial just reported that mazdutide, a synthetic peptide mimicking the natural hormone oxyntomodulin, cut average body weight by about 12 kg over 26 weeks and trimmed waist circumference significantly. The study involved over 400 adults with obesity, and the drop in triglycerides and HbA1c was notable.
I’m intrigued yet cautious. A 12‑kg loss in a short trial is impressive, but the drug’s side‑effect profile, nausea, diarrhea, and occasional hypoglycemia, seemed harsher than I’d expect from a well‑tolerated GLP‑1 analogue. In my own protocols, I’ve seen GLP‑1s at 3–4 mg weekly give 4–5 kg loss with manageable GI upset. If mazdutide’s GI profile is similar but the weight loss is higher, it could be a game‑changer, but it also raises questions about long‑term tolerance, dosage escalation, and off‑target effects.
Do you think the 10‑week “rapid decline” in appetite could mask a rebound once the drug is stopped, or could the dual rencontré of GLP‑1 and GLP‑2 receptors truly sustain the effect?
Community discussion - research and educational context only. Not medical advice.